Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
Add more filters










Publication year range
1.
BMJ Open Respir Res ; 4(1): e000198, 2017.
Article in English | MEDLINE | ID: mdl-29071074

ABSTRACT

INTRODUCTION: Pulmonary arteriovenous malformations (PAVMs) may not be amenable to treatment by embolisation or surgical resection, and many patients are left with significant hypoxaemia. Lung transplantation has been undertaken. There is no guidance on selection criteria. METHODS: To guide transplantation listing assessments, the outcomes of the six patients who had been considered for transplantation were compared with a similarly hypoxaemic patient group recruited prospectively between 2005 and 2016 at the same UK institution. RESULTS: Six patients had been formally considered for lung transplantation purely for PAVMs. One underwent a single lung transplantation for diffuse PAVMs and died within 4 weeks of surgery. The other five were not transplanted, in four cases at the patients' request. Their current survival ranges from 16 to 27 (median 21) years post-transplant assessment. Of 444 consecutive patients with PAVMs recruited between 2005 and 2016, 42 were similarly hypoxaemic to the 'transplant-considered' cohort (SaO2 <86.5%). Hypoxaemic cohorts maintained arterial oxygen content (CaO2) through secondary erythrocytosis and higher haemoglobin. The 'transplant-considered' cohort had similar CaO2 to the hypoxaemic comparator group, but higher Medical Research Council (MRC) dyspnoea scores (p=0.023), higher rates of cerebral abscesses (p=0.0043) and higher rates of venous thromboemboli (p=0.0009) that were evident before and after the decision to list for transplantation. CONCLUSIONS: The non-transplanted patients demonstrated marked longevity. Symptoms and comorbidities were better predictors of health than oxygen measurements. While a case-by-case decision, weighing survival estimates and quality of life will help patients in their decision making, the data suggest a very strong case must be made before lung transplantation is considered.

2.
Ann Am Thorac Soc ; 14(6): 903-911, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28267932

ABSTRACT

RATIONALE: PaO2 and SaO2 are commonly measured in respiratory practice, but arterial oxygen content (CaO2) refers to the volume of oxygen delivered to the tissues per unit blood volume. CaO2 is calculated from SaO2 and the hemoglobin concentration in blood, recognizing that each gram of hemoglobin can transport approximately 1.34 ml of oxygen when fully saturated. OBJECTIVES: To prospectively evaluate serial changes in CaO2 in humans, incorporating and excluding dynamic changes to oxygenation and hemoglobin parameters that may occur during life. METHODS: A cohort of 497 consecutive patients at risk of both hypoxemia and anemia were recruited. The patients had radiologically proven pulmonary arteriovenous malformations (PAVMs), which result in hypoxemia due to right-to-left shunting, and concurrent hereditary hemorrhagic telangiectasia, which placed them at risk of iron deficiency anemia due to recurrent hemorrhagic iron losses. Presentation SaO2 (breathing room air, by pulse oximetry), hemoglobin, red cell and iron indices were measured, and CaO2 calculated as SaO2 × hemoglobin × 1.34 ml/g. Serial measurements were evaluated in 100 cases spanning up to 32.1 (median, 10.5) years. RESULTS: Presentation CaO2 ranged from 7.6 to 27.5 (median, 17.6) ml/dl. CaO2 did not change appreciably across the SaO2 quartiles. In contrast, hemoglobin ranged from 5.9 to 21.8 g/dl (median, 14.1 g/dl), with a linear increase in CaO2 across hemoglobin quartiles. After PAVM embolization and an immediate increase in SaO2, hemoglobin fell and CaO2 was unchanged 1.6-12 (median, 4) months later. When hemoglobin fell because of iron deficiency, there was no change in SaO2. Similarly, when hemoglobin rose after iron treatment, there was no change in SaO2, and the expected CaO2 increment was observed. These relationships were not evident during pregnancy when hemoglobin fell, and PAVMs usually deteriorated: in pregnancy SaO2 commonly increased, and serial CaO2 values (incorporating hemodilution/anemia) more accurately reflected deteriorating PAVM status. An apparent fall in CaO2 with age in females was attributable to the development of iron deficiency. There was an unexplained increase in CaO2 with age in follow-up of males after embolization. CONCLUSIONS: Hemoglobin/CaO2 should be further incorporated into oxygenation considerations. More attention should be given to modest changes in hemoglobin that substantially modify CaO2.


Subject(s)
Anemia/blood , Arteriovenous Malformations/complications , Arteriovenous Malformations/therapy , Hemoglobins/analysis , Hypoxia/blood , Adult , Blood Gas Analysis , Embolization, Therapeutic , Female , Humans , Iron/blood , London , Lung/blood supply , Male , Middle Aged , Multivariate Analysis , Oximetry , Oxygen/blood , Pregnancy , Prospective Studies , Pulmonary Artery/abnormalities , Pulmonary Veins/abnormalities , Regression Analysis
3.
Respir Physiol Neurobiol ; 241: 53-57, 2017 07.
Article in English | MEDLINE | ID: mdl-28259748

ABSTRACT

Nitric oxide was introduced over 30 years ago as a test gas for alveolar capillary diffusion. As for CO its transfer has been interpreted according to the Roughton Forster relationship: 1/DL=1/DM+1/θVc. There has been disagreement, since the first measurements of DLNO, over whether θNO is infinite and thus DLNO=DMNO. There is overwhelming in vitro evidence that θNO is finite yet several groups (Coffman et al., 2017; Tamhane et al., 2001) use an infinite value in vivo. They also assume that DMNO is greater than twice DMCO, making DMCO less than that predicted by the physical laws of diffusion. Finally some (Coffman et al., 2017) recommend use of Reeve and Park's value for θCO (Reeves and Park, 1992; Coffman et al., 2017) rather than Forster's (Forster, 1987). Their grounds for doing so are that the combination of an infinite theta NO, an empirical value for DMNO/DMCO (>2.0) and Reeve and Park's θCO gives a value of DMCO (using a combined DLNO-DLCO analysis) which agrees with the DMCO value calculated separately by the classical two-stage oxygen technique of Roughton and Forster. In this paper we examine whether there are physiological reasons for assuming that DMNO is over twice DMCO in vivo. We are critical of Reeves and Park's estimate for the 1/θCO-PO2 relationship. We review in vitro estimates of θCO in the light of Guenard et al.'s recent in vivo estimate.


Subject(s)
Carbon Monoxide/blood , Nitric Oxide/blood , Humans , Models, Cardiovascular , Pulmonary Diffusing Capacity
4.
Eur Respir J ; 49(2)2017 02.
Article in English | MEDLINE | ID: mdl-28179436

ABSTRACT

Diffusing capacity of the lung for nitric oxide (DLNO), otherwise known as the transfer factor, was first measured in 1983. This document standardises the technique and application of single-breath DLNO This panel agrees that 1) pulmonary function systems should allow for mixing and measurement of both nitric oxide (NO) and carbon monoxide (CO) gases directly from an inspiratory reservoir just before use, with expired concentrations measured from an alveolar "collection" or continuously sampled via rapid gas analysers; 2) breath-hold time should be 10 s with chemiluminescence NO analysers, or 4-6 s to accommodate the smaller detection range of the NO electrochemical cell; 3) inspired NO and oxygen concentrations should be 40-60 ppm and close to 21%, respectively; 4) the alveolar oxygen tension (PAO2 ) should be measured by sampling the expired gas; 5) a finite specific conductance in the blood for NO (θNO) should be assumed as 4.5 mL·min-1·mmHg-1·mL-1 of blood; 6) the equation for 1/θCO should be (0.0062·PAO2 +1.16)·(ideal haemoglobin/measured haemoglobin) based on breath-holding PAO2 and adjusted to an average haemoglobin concentration (male 14.6 g·dL-1, female 13.4 g·dL-1); 7) a membrane diffusing capacity ratio (DMNO/DMCO) should be 1.97, based on tissue diffusivity.


Subject(s)
Blood Volume , Nitric Oxide/blood , Pulmonary Alveoli/blood supply , Pulmonary Diffusing Capacity/standards , Adolescent , Adult , Aged , Aged, 80 and over , Capillary Permeability , Carbon Monoxide/blood , Female , Hemoglobins/analysis , Humans , Linear Models , Male , Middle Aged , Oxygen/blood , Young Adult
7.
Chest ; 146(3): 709-718, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24676541

ABSTRACT

BACKGROUND: Patients with pulmonary arteriovenous malformations (PAVMs) are unusual because hypoxemia results from right-to-left shunting and not airway or alveolar disease. Their surprisingly well-preserved exercise capacity is not generally appreciated. METHODS: To examine why exercise tolerance is preserved, cardiopulmonary exercise tests were performed while breathing room air in 21 patients with radiologically proven PAVMs, including five restudied 3 to 12 months after embolization when their PAVMs had regressed. Where physiologic matching was demonstrable, comparisons were made with 12 healthy control subjects. RESULTS: The majority of patients achieved their predicted work rate despite a resting arterial oxygen saturation (SaO2) of 80% to 96%. Peak work rate and oxygen consumption (VO2) were no lower in patients with more hypoxemia. Despite higher SaO2 following embolization (median, 96% and 90%; P = .009), patients achieved similar work rates and similar peak VO2. Strikingly, treated patients reset to virtually identical peak oxygen pulses (ie, VO2 per heart beat) and in many cases to the same point on the peak oxygen pulse/work rate plot. The 21 patients had increased minute ventilation (VE) for given increases in CO2 production (VE/VCO2 slope), but perceived dyspnea was no greater than in the 12 control subjects or in the same patients before compared to after embolization comparison. Overall, work rate and peak VO2 were associated not with oxygenation parameters but with VE/VCO2 slope, BMI, and anaerobic threshold. CONCLUSIONS: Patients with hypoxemia and PAVMs can maintain normal oxygen delivery/VO2 during peak exercise. Following improvement of SaO2 by embolization, patients appeared to reset compensatory mechanisms and, as a result, achieved similar peak VO2 per heart beat and peak work rates.


Subject(s)
Arteriovenous Fistula/physiopathology , Exercise Test , Exercise Tolerance/physiology , Hypoxia/physiopathology , Physical Endurance/physiology , Pulmonary Artery/abnormalities , Pulmonary Veins/abnormalities , Aged , Anaerobic Threshold/physiology , Body Mass Index , Carbon Dioxide/metabolism , Case-Control Studies , Female , Humans , Male , Middle Aged , Oxygen Consumption/physiology , Pulmonary Artery/physiopathology , Pulmonary Veins/physiopathology
12.
Eur Respir J ; 41(2): 453-61, 2013 Feb.
Article in English | MEDLINE | ID: mdl-22936707

ABSTRACT

The transfer factor of the lung for nitric oxide (T(L,NO)) is a new test for pulmonary gas exchange. The procedure is similar to the already well-established transfer factor of the lung for carbon monoxide (T(L,CO)). Physiologically, T(L,NO) predominantly measures the diffusion pathway from the alveoli to capillary plasma. In the Roughton-Forster equation, T(L,NO) acts as a surrogate for the membrane diffusing capacity (D(M)). The red blood cell resistance to carbon monoxide uptake accounts for ~50% of the total resistance from gas to blood, but it is much less for nitric oxide. T(L,NO) and T(L,CO) can be measured simultaneously with the single breath technique, and D(M) and pulmonary capillary blood volume (V(c)) can be estimated. T(L,NO), unlike T(L,CO), is independent of oxygen tension and haematocrit. The T(L,NO)/T(L,CO) ratio is weighted towards the D(M)/V(c) ratio and to α; where α is the ratio of physical diffusivities of NO to CO (α=1.97). The T(L,NO)/T(L,CO) ratio is increased in heavy smokers, with and without computed tomography evidence of emphysema, and reduced in the voluntary restriction of lung expansion; it is expected to be reduced in chronic heart failure. The T(L,NO)/T(L,CO) ratio is a new index of gas exchange that may, more than derivations from them of D(M) and V(c) with their in-built assumptions, give additional insights into pulmonary pathology.


Subject(s)
Carbon Monoxide/metabolism , Nitric Oxide/metabolism , Respiratory Function Tests/methods , Blood Gas Analysis , Exercise/physiology , Humans , Lung Diseases/diagnosis , Lung Diseases/physiopathology , Pulmonary Diffusing Capacity/physiology
13.
Am J Respir Crit Care Med ; 186(2): 132-9, 2012 Jul 15.
Article in English | MEDLINE | ID: mdl-22538804

ABSTRACT

The single-breath carbon monoxide diffusing capacity (DL(CO)) is the product of two measurements during breath holding at full inflation: (1) the rate constant for carbon monoxide uptake from alveolar gas (kco [minute(-1)]) and (2) the "accessible" alveolar volume (Va). kco expressed per mm Hg alveolar dry gas pressure (Pb*) as kco/Pb*, and then multiplied by Va, equals Dl(CO); thus, Dl(CO) divided by Va (DL(CO)/Va, also called Kco) is only kco/Pb* in different units, remaining, essentially, a rate constant. The notion that DL(CO)/Va "corrects" DL(CO) for reduced Va is physiologically incorrect, because DL(CO)/Va is not constant as Va changes; thus, the term Kco reflects the physiology more appropriately. Crucially, the same DL(CO) may occur with various combinations of Kco and Va, each suggesting different pathologies. Decreased Kco occurs in alveolar-capillary damage, microvascular pathology, or anemia. Increased Kco occurs with (1) failure to expand normal lungs to predicted full inflation (extrapulmonary restriction); or (2) increased capillary volume and flow, either globally (left-to-right intracardiac shunting) or from flow and volume diversion from lost or damaged units to surviving normal units (e.g., pneumonectomy). Decreased Va occurs in (1) reduced alveolar expansion, (2) alveolar damage or loss, or (3) maldistribution of inspired gases with airflow obstruction. Kco will be greater than 120% predicted in case 1, 100-120% in case 2, and 40-120% in case 3, depending on pathology. Kco and Va values should be available to clinicians, as fundamental to understanding the clinical implications of DL(CO). The diffusing capacity for nitric oxide (DL(NO)), and the DL(NO)/DL(CO) ratio, provide additional insights.


Subject(s)
Carbon Monoxide/pharmacokinetics , Pulmonary Diffusing Capacity/physiology , Exercise/physiology , Humans , Lung/metabolism , Lung/physiology , Lung Diseases/metabolism , Lung Diseases/physiopathology , Lung Volume Measurements , Pulmonary Alveoli/metabolism , Pulmonary Alveoli/physiology , Respiratory Function Tests/methods
SELECTION OF CITATIONS
SEARCH DETAIL
...